UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 20, 2022
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification
No.)
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (203 ) 458-7100
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on
which registered
|
||
|
|
|
|
||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01. |
Other Events.
|
On December 20, 2022, Quantum-Si Incorporated issued a press release announcing the commercial availability of Platinum™, the world’s first
next-generation single-molecule protein sequencing platform. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01 |
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
|
Exhibit
No.
|
Description
|
|
|
Press Release dated December 20, 2022
|
||
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
QUANTUM-SI INCORPORATED
|
||
|
By:
|
/s/ Claudia Drayton
|
|
|
Name:
|
Claudia Drayton
|
|
|
Title:
|
Chief Financial Officer
|
|
|
Date: December 20, 2022
|
||
Exhibit 99.1
Quantum-Si Announces Commercial Availability of PlatinumTM, the World’s First
Next-Generation Single-Molecule Protein Sequencing Platform
Quantum-Si combines Time Domain Sequencing™ and Semiconductor Chip Technology to Advance Drug Discovery and Diagnostics and Accelerate Scientific
Breakthroughs, Helping People to Live Healthier and Longer Lives
Company Appoints Life Science Veteran Grace Johnston, PhD, as Chief Commercial Officer
Key Takeaways:
| ● |
The accessibility gained when using Platinum™ is expected to transform science and understanding of the proteome by unlocking unprecedented insights about the human body — just as the advent of next-generation
DNA sequencing revolutionized our knowledge of the human genome over the past two decades.
|
| ● |
The elegant simplicity of this next-generation protein sequencing platform enables
broad-scale access to proteomic data, positioning Platinum™ as a critical instrument for the future of proteomics research.
|
| ● |
The world’s first proven protein sequencing technology is available immediately for
ordering with shipments beginning in Q1 2023.
|
| ● |
Grace Johnston, PhD, has been appointed as the Company’s Chief Commercial Officer to lead global sales and commercial activities.
|
GUILFORD, Conn. -- December 20, 2022 -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the commercial availability of Platinum™, the world’s first next-generation single-molecule protein
sequencing platform. Platinum will be offered at an unprecedented low price-point of $70,000, while its small 19.5 inch by 8.5
inch footprint benchtop design is poised to greatly improve access to high-resolution protein sequencing data, ultimately accelerating
breakthroughs across scientific disciplines—from drug discovery to biotech—and helping people live healthier and longer lives.
The launch of Platinum marks Quantum-Si’s
movement out of almost a decade of stealth innovation. The Company was founded in 2013 by world-renowned scientist, entrepreneur, and National Medal of Technology and
Innovation recipient Dr. Jonathan Rothberg, an original pioneer of next generation genome sequencing. Jeff Hawkins was appointed CEO in October and brings extensive experience from the life-sciences and diagnostics space, including senior
leadership positions at Illumina. With many on the leadership team having played an active role in the advent of next-generation sequencing technology, Quantum-Si is well positioned to disrupt the current state of protein sequencing.
“Next-generation protein sequencing represents the vanguard of new
therapeutic discovery, however, no other company has met the promise of delivering an accessible single-molecule protein sequencing platform – until today,” said Jeff Hawkins, CEO of Quantum-Si. “Our ability to both discover and characterize
potential protein targets has been critically limited by current technology. Platinum delivers on a decade’s long mission to
dramatically improve access and scalability of single-molecule protein sequencing.”
Before today, proteomics technology has been hindered by its use of large expensive machinery, technically challenging and time-consuming protocols, and a lack of custom probes that can reliably
distinguish between amino acids, much less those with post translational modifications. In contrast, Quantum-Si’s next-generation sequencing system leverages
Time Domain Sequencing™ technology which alleviates this hurdle by monitoring for amino-acid specific patterns in fluorescent probe behavior. This means that a single probe can be used for the robust identification of multiple distinct amino
acids, including those containing post translational modifications. This approach provides a sensitive scalability that eliminates roadblocks of complex chemistry and large, expensive equipment utilized by other
technologies, while providing the sensitivity, scalability, and accessibility needed to accelerate biomedical research.
“We learned from the success of next-generation DNA sequencing how to move beyond big machines, expensive facilities and the need for significant training, and
we saw the benefits of placing the power of sequencing into the hands of individual researchers,” said Dr. Jonathan Rothberg, Founder of Quantum-Si. “Now with the invention of next-generation Protein sequencing with Platinum we’ve gone directly to
the desktop with a simple to use system that works the way our customers do.”
The Company also announced it has appointed Grace Johnston, PhD, to the position of Chief Commercial Officer. In this role, Dr. Johnston will have global
responsibility for all commercial activity including sales, marketing, and customer support. Dr. Johnston brings a depth of experience in go-to-market commercial strategy to Quantum-Si. She joins from Fortis Life Sciences where she served as CCO
for over two years. Prior to Fortis, she held leadership positions at multinational corporations such as Merck Millipore and Sartorius.
"With Platinum’s advanced capabilities and innovative technology, customers will be able to uncover new insights within the proteome and make breakthrough
therapeutic discoveries that were previously impossible,” said Dr. Johnston. “I am thrilled to join a leadership team helping scientists answer these important questions about the proteome. We believe Platinum will drive the next generation of
protein research and unlock the full potential of these important biological molecules.”
Quantum-Si is currently taking orders for Platinum™ and is set to begin shipping instruments in the first quarter of 2023. For more information about Platinum, please visit the Quantum-Si website.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing
the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to
advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com.
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private
Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events.
Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words
or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products
and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the
Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock
on The Nasdaq Stock Market; the ability to recognize the benefits of the business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key
employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization
activities; the potential attributes and benefits of the Company's products and services; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the
Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing
or engaged in the development or commercialization of products and services that the Company is developing; the size and growth potential of the markets for the Company's future products and services, and its ability to serve those markets, either
alone or in partnership with others; the pricing of the Company's products and services following commercial launch; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the
Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company’s Annual Report for the fiscal year ended December 31, 2021, and in the Company's other filings with the SEC. The Company cautions that
the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or
undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
Investor Contact
Juan Avendano
ir@quantum-si.com
Media Contact
Michael Sullivan
media@quantum-si.com